{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:27:02Z","timestamp":1790368022885,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We present a case of CVID complicated by granulomatous interstitial lung disease (GLILD). This patient clinical course was further complicated by COVID-19 infection. This is only the 2nd known case report of COVID 19 in CVID with GLILD. The clinical course and outcome of COVID 19 infection with common variable immunodeficiency (CVID) and GLILD is not well known.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Our patient met the clinical features of CVID secondary to low IgG\/IgA, recurrent infections, and failure to respond to pneumococcal vaccination. He was treated with monthly maintenance IVIG therapy. Our patient also was diagnosed with co-existing GLILD that despite IVIG treatment was progressing. The patient needed to be started on Rituxan and Mycophenolate mofetil to achieve control but unfortunately became infected with COVID19 delaying his treatment for GLILD. Our patient only suffered from mild COVID 19 infection and was able to make antibodies to this. We believe severe infection was avoided as his CVID was well controlled with IVIG therapy despite progression of his granulomatous interstitial lung disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, our patient with CVID with co-existing biopsy proven granulomatous interstitial lung disease despite being very high risk for severe COVID 19 infections only had mild infection. This was believed to be due to well controlled CVID with IVIG therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-021-00600-y","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T15:02:55Z","timestamp":1632668575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Common variable immunodeficiency (CVID) with granulomatous interstitial lung disease (GLILD) and SARS COVID-19 infection: case report and review of literature"],"prefix":"10.1186","volume":"17","author":[{"given":"Debendra","family":"Pattanaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunah","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fahhoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,26]]},"reference":[{"key":"600_CR1","unstructured":"Your health: people with certain medical conditions and risks of severe Covid-19 infections. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html. Accessed on 2 May 2021."},{"issue":"12","key":"600_CR2","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1164\/rccm.202010-3918ED","volume":"202","author":"AJ Podolanczuk","year":"2020","unstructured":"Podolanczuk AJ, Richeldi L. COVID-19 and interstitial lung disease: keep them separate. Am J Respir Crit Care Med. 2020;202(12):1614\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"600_CR3","first-page":"31102","volume":"S2213\u20132198","author":"HE Ho","year":"2020","unstructured":"Ho HE, Mathew S, Peluso MJ, Cunningham-Rundles C. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. J Allergy Clin Immunol Pract. 2020;S2213\u20132198(20):31102\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"600_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.anai.2020.08.017","volume":"126","author":"J Mullur","year":"2021","unstructured":"Mullur J, Wang A, Feldweg A. A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency. Ann Allergy Asthma Immunol. 2021;126(1):90\u20132.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"600_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jaip.2017.01.021","volume":"5","author":"JR Hurst","year":"2017","unstructured":"Hurst JR, Verma N, Lowe D, Baxendale HE, et al. British Lung Foundation\/United Kingdom Primary Immunodeficiency Network Consensus Statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2017;5(4):938\u201345.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"600_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","volume":"4","author":"FA Bonilla","year":"2016","unstructured":"Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(1):38\u201359.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"600_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1006\/clim.1999.4725","volume":"92","author":"C Cunningham-Rundles","year":"1999","unstructured":"Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34\u201348.","journal-title":"Clin Immunol"},{"issue":"2","key":"600_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2020.07.021","volume":"147","author":"JW Verbsky","year":"2021","unstructured":"Verbsky JW, Hintermeyer MK, Simpson PM, Feng M, Barbeau J, Rao N, Cool CD, Sosa-Lozano LA, Baruah D, Hammelev E, Busalacchi A, Rymaszewski A, Woodliff J, Chen S, Bausch-Jurken M, Routes JM. Rituximab, and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol. 2021;147(2):704-712.e17. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.021 (PMID: 32745555).","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"600_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.anai.2020.06.006","volume":"125","author":"R Aljaberi","year":"2020","unstructured":"Aljaberi R, Wishah K. Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2020;125(3):349\u201350.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"600_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.anai.2020.04.033","volume":"125","author":"L Fill","year":"2020","unstructured":"Fill L, Hadney L, Graven K, Persaud R, Hostoffer R. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(1):112\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","volume":"20","author":"N Gharebaghi","year":"2020","unstructured":"Gharebaghi N, Nejadrahim R, Mousavi SJ, et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20:786.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"600_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2217\/imt-2020-0095","volume":"12","author":"JM D\u00edez","year":"2020","unstructured":"D\u00edez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy. 2020;12(8):571\u20136.","journal-title":"Immunotherapy"},{"issue":"1","key":"600_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","volume":"146","author":"I Quinti","year":"2020","unstructured":"Quinti I, Lougaris V, Milito C, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146(1):211\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"600_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd0110","author":"M Roschewski","year":"2020","unstructured":"Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.abd0110.","journal-title":"Sci Immunol"},{"key":"600_CR15","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1182\/blood.2020006288","volume":"135","author":"SP Treon","year":"2020","unstructured":"Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135:1912\u20135.","journal-title":"Blood"},{"issue":"2","key":"600_CR16","first-page":"AB66","volume":"147","author":"Chang","year":"2021","unstructured":"Chang, et al. A case of mild COVID19 infection in a teenager with common variable immunodeficiency and granulomatous interstitial lung disease on replacement immunoglobulin and infliximab. JACI Pract. 2021;147(2):AB66.","journal-title":"JACI Pract"},{"issue":"3","key":"600_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jaip.2018.10.041","volume":"7","author":"L Cereser","year":"2019","unstructured":"Cereser L, De Carli R, Girometti R, De Pellegrin A, Reccardini F, Frossi B, De Carli M. Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency. J Allergy Clin Immunol Pract. 2019;7(3):1055-1057.e2. https:\/\/doi.org\/10.1016\/j.jaip.2018.10.041 (PMID: 30408616).","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"17","key":"600_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12948-019-0113-3","volume":"6","author":"A Pecoraro","year":"2019","unstructured":"Pecoraro A, Crescenzi L, Galdiero MR, Marone G, Rivellese F, Rossi FW, de Paulis A, Genovese A, Spadaro G. Immunosuppressive therapy with rituximab in common variable immunodeficiency. Clin Mol Allergy. 2019;6(17):9. https:\/\/doi.org\/10.1186\/s12948-019-0113-3 (PMID:31080365; PMCID:PMC6501382).","journal-title":"Clin Mol Allergy"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-021-00600-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T15:11:30Z","timestamp":1632669090000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00600-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00600-y","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,26]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}